Pulse Biosciences (NASDAQ:PLSE) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other equities analysts have also recently issued reports on the stock. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pulse Biosciences in a research report on Friday. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $30.00.

Pulse Biosciences Price Performance

Shares of Pulse Biosciences stock opened at $21.42 on Friday. Pulse Biosciences has a one year low of $12.56 and a one year high of $26.30. The business’s 50 day simple moving average is $16.35 and its two-hundred day simple moving average is $16.08. The stock has a market capitalization of $1.45 billion, a P/E ratio of -19.83 and a beta of 1.77.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. The company had revenue of ($0.09) million for the quarter, compared to analysts’ expectations of $0.23 million.

Insiders Place Their Bets

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $23.63, for a total transaction of $472,600.00. Following the transaction, the insider owned 43,298 shares in the company, valued at approximately $1,023,131.74. This represents a 31.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 80,000 shares of company stock worth $1,876,200. Insiders own 74.60% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its position in shares of Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the period. KLP Kapitalforvaltning AS increased its stake in shares of Pulse Biosciences by 136.0% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after acquiring an additional 3,400 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in Pulse Biosciences by 184.5% during the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after acquiring an additional 5,748 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Q4 EPS beat analyst expectations — Pulse reported a loss of $0.26 per share vs. consensus -$0.32, beating estimates and showing a smaller-than-expected loss. This helped limit downside after the print. Read More.
• Positive Sentiment: Clinical/business update: company highlighted strong procedural results for its endocardial nPulse catheter (100% freedom from AF at 6 months, 96% procedural success), supporting long‑term product potential and commercialization story. Read More.
• Neutral Sentiment: Investor outreach: Pulse will present at the 46th Annual TD Cowen Healthcare Conference — useful for visibility and investor Q&A but not an immediate revenue driver. Read More.
• Neutral Sentiment: Inducement equity grants: the board awarded equity inducements to two new employees under Nasdaq Rule 5635(c)(4). Standard hiring practice; could be seen as modestly dilutive over time but routine. Read More.
• Negative Sentiment: Revenue missed expectations — reported revenue was effectively flat/negative ($-0.09M) vs. the consensus ~$0.23M, raising near-term commercialization and cash‑flow concerns for some investors. Read More.
• Negative Sentiment: Insider selling: recent filings show insiders sold roughly $0.94M combined in two transactions, which investors may interpret as a negative signal on near‑term insider conviction. Read More. Read More.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.